SCHEMBL8943574

SCHEMBL8943574

CC(C)c1ccc(C[C]=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.47
TYR P14679 2/20 0.46
PYCR1 P32322 1/20 0.43
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
ACACB O00763 1/20 0.40
RAB9A P51151 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 3/20 0.38
COPS5 Q92905 1/20 0.37
USP5 P45974 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3869438 0.83 PTGS1 (0.32) IDO1TYRPYCR1
SCHEMBL17497706 0.83 TSHR (0.36) IDO1TYRPYCR1RAB9AMEN1
SCHEMBL11221907 0.83 ADRB2 (0.45) IDO1
SCHEMBL1609724 0.82 IDO1 (0.47) IDO1TYRPYCR1HTR1DHTR1B
SCHEMBL11139354 0.80 CYP3A4 (0.42) KMT2ASMN1; SMN2
SCHEMBL8023647 0.79 PGK1 (0.36) MEN1KMT2A
SCHEMBL3956146 0.78 IDO1 (0.56) IDO1TYRPYCR1HTR1DHTR1B
SCHEMBL2702724 0.77 PTGS1 (0.47) MEN1KMT2A
SCHEMBL2294887 0.77 IDO1 (0.47) IDO1TYRPYCR1HTR1DHTR1B
SCHEMBL6810356 0.75 ESR1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4159267-A Novel silyl ester azetidine-2-sulfenate intermediates and process for preparing desacetoxycephalosporins ELI LILLY AND COMPANY (US) 1979-06-26 US claimed
US-20230242570-A1 METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-08-03 US disclosed
CN-109561680-A small molecule modulators of pantothenate kinase 圣朱德儿童研究医院 2019-04-02 CN disclosed
CN-101198333-A Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORP (US) 2008-06-11 CN disclosed
US-5532353-A Process for the preparation of halogenated β-lactam compounds BIOCHIMICA OPOS SPA (IT) 1996-07-02 US disclosed
EP-0570058-A2 Process for the preparation of halogenated beta-lactam compounds BIOCHIMICA OPOS SPA (IT) 1993-11-18 EP disclosed
US-4992544-A Intermediates for b-lactam antibiotics and b-lactamase inhibitor UNIVERSITY OF NOTRE DAME DU LAC (US) 1991-02-12 US disclosed
US-4533497-A N-ethylidene azetidinones ELI LILLY AND COMPANY (US) 1985-08-06 US disclosed
US-4281116-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1981-07-28 US disclosed
US-4260745-A 3-Halo cephalosporins ELI LILLY AND COMPANY (US) 1981-04-07 US disclosed
US-4061672-A Derivatives of 9-hydroxy-13-trans-prostenoic acid AMERICAN CYANAMID COMPANY (US) 1977-12-06 US disclosed
US-RE29469-E PROSTAGLANDINS; BRONCHODILATORS, HYPOTENSIVES, ANTIULCER AGENTS AMERICAN CYANAMID COMPANY (US) 1977-11-08 US disclosed
US-4042472-A Electrolytic process for 7-methoxy-3-exomethylenecepham compounds ELI LILLY AND COMPANY (US) 1977-08-16 US disclosed
US-4013651-A 3-SUBSTITUTED AMINO-CEPHALOSPORINS ELI LILLY AND COMPANY (US) 1977-03-22 US disclosed
US-3992377-A 3-Thio-substituted cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1976-11-16 US disclosed
US-3985737-A ANTIBACTERIAL AGENTS ELI LILLY AND COMPANY (US) 1976-10-12 US disclosed
US-3962227-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1976-06-08 US disclosed
US-3960844-A Preparation of 6-acylamino-2-methyl-2-halomethyl penams ELI LILLY AND COMPANY (US) 1976-06-01 US disclosed
US-3950406-A BRONCHODILATORS, HYPOTENSIVE, ANTIULCER AMERICAN CYANAMID COMPANY (US) 1976-04-13 US disclosed
US-3944545-A Process for preparing desacetoxycephalosporins ELI LILLY AND COMPANY (US) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242570-A1 METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER FBL, POLI, POLL IDO1 4559/4885TYR 2882/4885PYCR1 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.